US Biotech Says Drug Thwarted Muscle Loss in Wegovy Patients

An experimental drug from a US biotech helped prevent muscle loss in patients taking Novo Nordisk A/S’s Wegovy in a new study.

Patients taking Veru Inc’s experimental treatment enobosarm with Wegovy had a 71% reduction in lean mass loss after 16 weeks, compared with those just taking Wegovy and a placebo, the US biotech said Monday, citing initial clinical trial results.

Veru and others are racing to crack the problem of preventing muscle loss as more patients turn to blockbuster obesity drugs to lose weight.

Read More: Beyond Wegovy, the Search Is On for Muscle-Saving Obesity Drugs

When ...